|
Extracorporeal Support for Respiratory Insufficiency (ECMO) Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Extracorporeal Support for Respiratory Insufficiency (ECMO) conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Extracorporeal Support for Respiratory Insufficiency (ECMO) Clinical research trials and Extracorporeal Support for Respiratory Insufficiency (ECMO) healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Extracorporeal Support for Respiratory Insufficiency (ECMO). Extracorporeal Support for Respiratory Insufficiency (ECMO) Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Extracorporeal Support for Respiratory Insufficiency (ECMO) clinical trial. Participants typically obtain the most effective healthcare available for their Extracorporeal Support for Respiratory Insufficiency (ECMO) condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Extracorporeal Support for Respiratory Insufficiency (ECMO)  Extracorporeal Support for Respiratory Insufficiency (ECMO)
Extracorporeal Support for Respiratory Insufficiency (ECMO)
For Condition: Acute Respiratory Failure,Lung Diseases
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To evaluate indications for the use and efficacy of extracorporeal membrane oxygenators (ECMO's) for the support of patients with potentially reversible acute respiratory failure.
Details: BACKGROUND: The report of the Task Force on Respiratory Diseases identified a clinical syndrome of acute respiratory insufficiency (ARI) and estimated that approximately 60,000 Americans die of ARI yearly. ARI was not precisely defined; indeed, the Task Force realized that pathologists do not recognize ARI. The Task Force pointed out that no diagnostic tests for early detection of ARI exist, that the incidence and prevalence of the disease are not known, and that existing therapy is supportive and nonspecific (diuretics, corticosteroids, etc.). The pathogenesis of the syndrome, the mechanism of interstitial edema, the defenses of the lung against agents causing ARI, and the ultrastructural pathology and natural history of the disease were virtually unknown. The Task Force indicated a need for Respiratory Care Centers with highly trained personnel that could reduce mortality from ARI. This clinical trial grew out of the Task Force report. Nine participating centers defined ARI in clinical and physiological terms and agreed to a prospective randomized study for 3 years to compare treatment of severe ARI by conventional means with treatment by extracorporeal membrane oxygenators. Animal studies have shown that ECMO's can provide one to two weeks' support for the lungs without serious blood damage, in contrast to bubble oxygenators, which allow complete pulmonary bypass for approximately 6 hours, after which severe blood damage occurs at the direct blood-gas interface. If patients with hypoxia secondary to acute reversible lung injury can be supported with ECMO's until the lung lesion heals, improvement in survival rates and avoidance of the hazards of conventional therapy may result. The trial, now completed, was conducted at nine clinical centers in the United States. DESIGN NARRATIVE: Randomized, non-blind, fixed sample; 90 eligible patients were randomly assigned to a group receiving extracorporeal membrane oxygenation plus conventional therapy or to a group receiving conventional therapy.
Eligibility:
Study Type: Interventional, Treatment, Randomized
Minimum Age/Maximum Age: 12 Years/65 Years
Genders: Both
Protocol Entry Criteria: Men and women, ages 12 to 65, not stratified as to ethnic group, who had potentially reversible acute respiratory failure.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertBartlett, , University of California, Irvine
Additional Information:
Study ID Numbers: 200;
Study Start Date: June 1974
Record last reviewed: January 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000562
Other Lung Diseases Studies:
1. Extracorporeal Support for Respiratory Insufficiency (ECMO)
Related Studies:
Other Lung Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Extracorporeal Support for Respiratory Insufficiency (ECMO)
|
|
|
|
|
|
|
|
